Novel therapies for sepsis: antiendotoxin therapies

Bibliography

• HEUMANN D, GLAUSER MP, CALANDRA T: Molecular basis of host-pathogen interaction in septic shock. Curr. Opin. Microbial (1998) 1:49–55.
   PubMed Web of Science ®Google Scholar
• HEMMI H, TAKEUCHI 0, KAWAI T et al.: A Toll-like receptor recognizes bacterial DNA. Nature (2000) 408:740–745.
   Google Scholar
• BAUER S, KIRSCHNING CJ, HACKER H et al: Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc. Nati Acad. Sd. USA (2001) 98:9237–9242.
   PubMed Web of Science ®Google Scholar
• SPARWASSER T, MIETHKE T, LIPFORD G et al: Macrophages sense pathogens via DNA motifs: induction of tumor necrosis factor-alpha-mediated shock. Lid. I Immunol (1997) 27:1671–1679.
   Web of Science ®Google Scholar
• SPARWASSER T, MIETHKE T, LIPFORD G et al: Bacterial DNA causes septic shock. Nature (1997) 386:336–337.
   PubMed Web of Science ®Google Scholar
• ALEXOPOULOU L, HOLT AC, MEDZHITOV R, FLAVELL RA: Recognition of double-stranded RNA and activation of NF-kappa B by Toll-like receptor 3. Nature (2001) 413:732–738.
   PubMed Web of Science ®Google Scholar
• RIETSCHEL ET, BRADE H: Bacterial endotwdns. Sci. Am. (1992) 267:54–61.
   PubMed Web of Science ®Google Scholar
• BRAUDE Al, DOUGLAS H: Passive immunization against the local shwartzman reaction. Immunol (1972) 108:505–512.
   Web of Science ®Google Scholar
• LYNN WA: Anti-endotoxin therapeutic options for the treatment of sepsis. Antimicrob. Clremotber. (1998) 41 (Suppl. A):71–80.
   Google Scholar
• •Review of antiendotoxin therapies.
   Google Scholar
• KUMAR A, KRIEGER A, SYMEONEIDES S, KUMAR A, PARRILLO JE: Myocardial dysfunction in septic shock: Part II. Role of cytokines and nitric oxide. j Cardiothorac. Vase. Anesth. (2001) 15:485–511.
   PubMed Web of Science ®Google Scholar
• •Thorough review of myocardial dysfunction in sepsis.
   Google Scholar
• MCCABE WR, GREENLY A: Immunization with R mutants of S. Minnesota. 1. Protection against challenge with hetrologus Gram-negative bacilli.' Immunol (1972) 108:601–610.
   Google Scholar
• RAETZ CH, ULEVITCH RJ, WRIGHT SD, SIBLEY CH, DING A, NATHAN CF: Gram-negative endotoxin: an extraordinary lipid with profound effects on eukaryotic signal transduction. FASEB.I. (1991) 5:2652–2660.
   PubMed Web of Science ®Google Scholar
• HELLMAN J, WARREN HS: Antiendotoxin Strategies. Infect. Dis. Clio. North Am. (1999) 13:371–379.
   PubMed Web of Science ®Google Scholar
• •Another recent review of antiendotoxin therapies.
   Google Scholar
• YU B, HAILMAN E, WRIGHT SD: Lipopolysaccharide binding protein and soluble CD14 catalyze exchange of phospholipids. Clio. Invest. (1997) 99:315–325.
   PubMed Web of Science ®Google Scholar
• PARK CT, WRIGHT SD: Plasma lipopolysaccharide binding protein is found associated with a particle containing apolipoprotein A-1, phospholipid, and factor H-related proteins. J. Biol. Chem. (1996) 271:18054–18060.
   PubMed Web of Science ®Google Scholar
• WURFEL MM, WRIGHT SD: Lipopolysaccharide binding protein and soluble CD14 transfer lipopolysaccharide to phospholipid bilayers. Preferential interaction with particular classes of lipid. Immunol (1997) 158:3925–3934.
   Google Scholar
• YU B, WRIGHT SD: Catalytic properties of lipopolysaccharide (LPS) binding protein. J. Biol. Chem. (1996) 271:4100–4105.
   PubMed Web of Science ®Google Scholar
• SCHUMANN RR, LEONG SR, FLAGGS GW et al: Structure and function of lipopolysaccharide binding protein. Science (1990) 249:1429–1431.
   PubMed Web of Science ®Google Scholar
• ULEVITCH RI, TOBIAS P: Recognition of endotoxin by cells leading to transmembrane signaling. Can: Biol. (1994) 6:125–130.
   Google Scholar
• HEUMANN D, GALLAY P, BARRAS C et al.: Control of LPS binding and LPS-induced TNF secretion in human peripheral blood monocytes. Immunol. (1992) 148:3505–3512.
   Web of Science ®Google Scholar
• MATTSSON E, ROLLOF J, VERHOEFJ,VAN DICK H, FLEER A: Serum induced potentiation of tumor necrosis factor alpha production by human monocytes in response to staphylococcal peptidoglycan: involvement of different serum factors. Infect. Immun. (1994) 62:3837–3843.
   PubMed Web of Science ®Google Scholar
• HEUMANN D, BARRAS C, DE JONGE B, SEVERIN A, GLAUSER MP, TOMASZ A: Gram-positive cell walls stimulate the synthesis of TNF alpha and IL-6 by human monocytes. Infect. Inman. (1994) 62:2715–2721.
   PubMed Web of Science ®Google Scholar
• LANDMANN R, MULLER B, ZIMMERLI W: CD14, new aspects of ligand and signal diversity. Microbes Infect. (2000) 2:295–304.
   PubMed Web of Science ®Google Scholar
• WRIGHT SD, RAMOS RA, TOBIAS PS, ULEVITCH RI, MATHISON IC: CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science (1990) 249:1431–1433.
   PubMed Web of Science ®Google Scholar
• INGALLS RR, GOLENBOCK DT: CD11c/CD18, a transmembrane signaling receptor for lipopolysaccharide. J. Exp. Med. (1995) 181:1473–1479.
   PubMed Web of Science ®Google Scholar
• WORFEL MM, HAILMAN E, WRIGHT SD: Soluble CD14 acts as a shuttle in the neutralization of lipopolysaccharide (LPS) by LPS-binding protein and reconstituted high density lipoprotein. I Exp. Med. (1995) 181:1743–1754.
   PubMed Web of Science ®Google Scholar
• BAZIL V, STROMINGER JL: Shedding asa mechanism of down-modulation of CD14 on stimulated human monocytes. Immunol. (1991) 147:1567–1574.
   Web of Science ®Google Scholar
• HAILMAN E, LICHENSTEIN HS, WURFEL MM et al: Lipopolysaccharide (LPS)-binding protein accelerates the binding of LPS to CD14. 1 Exp. Med. (1994) 179:269–277.
   Google Scholar
• KIRSCHNING CI, WESCHE H, AYRES TM, ROTHE M: Human Toll-like receptor 2 confers responsiveness to bacterial lipopolysaccharide. Exp. Med. (1998) 188:2091–2097.
   PubMed Web of Science ®Google Scholar
• PUGIN J, SCHARER-MALY CC, LETURCQ D, MORIARTY A, ULEVITCH RI, TOBIAS PS: Lipopolysaccharide activation of human endothelial and epithelial cells is mediated by lipopolysaccharide-binding protein and soluble CD14. Proc. Natl. Acad. Sci. USA (1993) 90:2744–2748.
   PubMed Web of Science ®Google Scholar
• ULMER Al, SALMALOUTI VT, RIETSCHEL ET, FLAD HD, DZIARSKY R: CD14, an innate immune receptor for various bacterial cell wall components. In: Endotoxin M Health and Disease Brade H, Opal S, Vogel S, Morrison D (Eds), Dekker, New York (1999):463–471.
   Google Scholar
• YANG RB, MARK MR, GRAY A et al.: Toll-like receptor-2 mediates lipopolysaccharide-induced cellular signaling. Nature (1998) 395:284–288.
   PubMed Web of Science ®Google Scholar
• KIRSCHNING CJ, WESCHE H, MERRILL AT, ROTHE M: Human Toll-like receptor 2 confers responsiveness to bacterial lipopolysaccharide. Exp. Med. (1998) 188:2091–2097.
   PubMed Web of Science ®Google Scholar
• HOSHINO K, TAKEUCHI 0, KAWAI T et al.: Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. I Immunol. (1999) 162:3749–3752.
   Google Scholar
• CHOW IC, YOUNG DW, GOLENBOCK DT, CHRIST WI, GUSOVSKY F: Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. J. Bia Chem. (1999) 274:10689–10692.
   PubMed Web of Science ®Google Scholar
• TAUSZIG S, JOUANGUY E, HOFFMANN JA, IMLER IL: Toll-related receptors and the control of antimicrobial peptide expression in Drosophila. Proc. Natl. Acad. Sci. USA (2000) 97:10520–10525.
   PubMed Web of Science ®Google Scholar
• TAKEUCHI 0, HOSHINO K, KAWAI T et al.: Differential roles of TLR2 and TLR4 in recognition of Gram-negative and Gram-positive bacterial cell wall components. Immunigt (1999) 11:443–451.
   Google Scholar
• LIEN E, SELLATI TI, YOSHIMURA A et al.: Toll-like receptor 2 functions as a pattern recognition receptor for diverse bacterial products. I Biol. Chem. (1999) 274:33419–33425.
   Web of Science ®Google Scholar
• LIEN E, MEANS TK, HEINE H et al: Toll-like receptor 4 imparts ligand-specific recognition of bacterial lipopolysaccharide. Clin. Invest. (2000) 105:497–504.
   Google Scholar
• BEUTLER B, POLTORAK A: The sole gateway to endotoxin response: how LPS was identified as TLR4, and its role in innate immunity. Drug Metab. Dispos. (2001) 29:474–478.
   PubMed Web of Science ®Google Scholar
• JIANG Q, AKASHI S, MIYAKE K, PETTY HR: Lipopolysaccharide induces physical proximity between CD14 and Toll-like receptor 4 (TLR4) prior to nuclear translocation of NF-kappa B. I Immunol. (2000) 165:3541–3544.
   PubMed Web of Science ®Google Scholar
• LAFLAMME N, RIVEST S: Toll-like receptor 4: the missing link of the cerebral innate immune response triggered by circulating Gram-negative bacterial cell wall components. FASEB (2001) 15:155–163.
   PubMed Web of Science ®Google Scholar
• ULEVITCH RI, TOBIAS PS: Recognition of Gram-negative bacteria and endotoxin by the innate immune system. Can: Opin. Immunol. (1999) 11:19–22.
   PubMed Web of Science ®Google Scholar
• FLEGAL WA, BAUMSTARK MW, WEINSTOCK C, BERG A, NORTOFF H: Prevention of endotoxin-induced monokine release by human low- and high-density lipoproteins and by apolipoprotein A-1. Infect. Inman. (1993) 61:5140–5146.
   PubMed Web of Science ®Google Scholar
• ELSBACH P, WEISS J: Prospects for use ofrecombined BPI in the treatment of Gram-negative bacterial infections. Infect. Agents Dis. (1995) 4:102–109.
   PubMedGoogle Scholar
• MUNFORD RS, HALL CL: Detoxification of bacterial lipopolysaccharide (endotwdns) by human neutrophil enzyme. Science (1986) 234:203–205.
   PubMed Web of Science ®Google Scholar
• CHEDID L, PARANT M, PARANT F, BOYER F: A proposed mechanism for natural immunity to enterobacterial pathogens. I Immunol. (1968) 100:292–306.
   PubMed Web of Science ®Google Scholar
• BRAUDE AE, JONES IL, DOUGLAS H: The behaviour of Escherichia coli endotoxin (somatic antigen) during infectious arthritis. Immunol. (1963) 90:297–
   Web of Science ®Google Scholar
• BARCLAY GR, SCOTT BB, WRIGHT IH, ROGERS PN, SMITH DE, PDXTON IR: Changes in anti-endotoxin IgG antibody and endotoxemia in three cases of Gram-negative septic shock. Circ. Shock (1989) 29:93–106.
   PubMedGoogle Scholar
• NYS M, DAMAS P, JOASSIN L, LAMY M: Sequential anti-core glycolipid immunoglobulin antibody activities in patients with and without septic shock and their relation to outcome. Ann. Surg. (1993) 217:300–306.
   Google Scholar
• GOLDIE AS, FEARON KC, ROSS IA et al.: Natural cytokine antagonists and endogenous antiendotoxin core antibodies in sepsis syndrome. The Sepsis Intervention Group. JAMA (1995) 274:172–177.
   PubMed Web of Science ®Google Scholar
• WAKEFIELD CH, BARCLAY GR, FEARON KC et al: Proinflammatory mediator activity, endogenous antagonists and the systemic inflammatory response in intra-abdominal sepsis. Scottish Sepsis Intervention Group. Br. J. Stow. (1998) 85:818–825.
   Google Scholar
• STRUTZ F, HELLER G, KRASEMANN K, KRONE B, MULLER GA: Relationship of antibodies to endotoxin core to mortality in medical patients with sepsis syndrome. Intensive Care Med. (1999) 25:435–444.
   PubMed Web of Science ®Google Scholar
• HAMILTON-DAVIES C, BARCLAY GR, CARDIGAN RA et al: Relationship between preoperative endotoxin immune status, gut perfusion, and outcome from cardiac valve replacement surgery. Chest (1997) 112:1189–1196.
   PubMed Web of Science ®Google Scholar
• BENNETT-GUERRERO E, AYUSO L, HAMILTON-DAVIES C et al.: Relationship of preoperative antiendotoxin core antibodies and adverse outcomes following cardiac surgery. JAMA (1997) 277:646–50.
   PubMed Web of Science ®Google Scholar
• ZIEGLER EJ, MCCUTCHAN JA, FIERER J et al: Treatment of Gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coil N Engl. J. Med. (1982) 307:1225–1230.
   Google Scholar
• •One of the first of a series of randomised trials of passive immunisation in sepsis.
   Google Scholar
• BAUMGARTNER JD, MCCUTCHAN JA, MELLE GV et al.: Prevention of Gram-negative shock and death in surgical patients by antibody to endotoxin core glycolipid. Lancet (1985) 8446:59–63.
   Google Scholar
• CALANDRA T, GLAUSER MP, SCHELLENKENS J, VERHOEF J: Treatment of Gram-negative septic shock with human IgG antibody to Escherichia coil J5: a prospective, double blind, randomized trial.," Infect. Dis. (1988) 158:312–319.
   Google Scholar
• J5 STUDY GROUP: Treatment of severeinfectious purpura in children with human plasma from donors immunized with Escherichia coliJ5: a prospective double-blind study. J. Infect. Dis. (1992) 165:695–701.
   PubMed Web of Science ®Google Scholar
• INTRAVENOUS IMMUNO GLOBULINCOLLABORATIVE STUDY GROUP: Prophylactic intravenous administration of standard immune globulin as compared with core-lipopolysaccharide immune globulin in patients at high risk of postsurgical infection. N Engl. J. Med. (1992) 327:234–240.
   PubMed Web of Science ®Google Scholar
• SMITH AL: Treatment of septic shock withimmunotherapy. Pharmacotherapy (1998) 18:565–580.
   PubMed Web of Science ®Google Scholar
• ALEJANDRIA MM, LANSANG MA, DANS LF, MANTARING JB: Intravenous immunoglobulin for treating sepsis and septic shock (Cochrane Review). Cochrane Database Syst. Rev (2002):CD001090.
   Google Scholar
• •Systematic review of immunoglobulin therapies in septic shock.
   Google Scholar
• TENG NN, KAPLAN HS, HERBERT JM et al: Protection against Gram-negative bacteremia and endotoxemia with monoclonal IgM antibodies. Proc. Nati Acad. Sci. USA (1985) 82:1790–1794.
   PubMed Web of Science ®Google Scholar
• ZIEGLER EJ, FISHER CJ, SPRUNG CLet al: Treatment of Gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin: A randomized, double blind, placebo-controlled trial. N Engl. J. Med. (1991) 324:429–436.
   PubMed Web of Science ®Google Scholar
• WORTEL CH, VON DER MOHLEN MA, VAN DEVENTER SJ et al: Effectiveness of human monoclonal anti-endotoxin antibody (HA-1A) in Gram-negative sepsis: relationship to endotoxin and cytokine levels. J. Infect. Dis. (1992) 166:1367–1374.
   PubMed Web of Science ®Google Scholar
• MCCLOSKEY RV, STRAUBE RC, SANDERS C, SMITH SM, SMITH CR: Treatment of septic shock with human monoclonal antibody HA-1A: A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. (1994) 121:1–5.
   PubMed Web of Science ®Google Scholar
• BIGATELLO LM, GREENE RE, SPRUNG CL et al.: HA-1A in septic patients with ARDS: results from the pivotal trial. Intensive Care Med. (1994) 20:328–334.
   PubMed Web of Science ®Google Scholar
• DERKX B, WITTES J, MCCLOSKEY Ret al: Randomized, placebo-controlled trial of HA-1A, a human monoclonal antibody to endotoxin, in children with meningococcal septic shock. Clin. Infect. Dis. (1999) 28:770–777.
   PubMed Web of Science ®Google Scholar
• NATIONAL COMMITTEE FOR THE EVALUATION OF CENTOXIN: The French National Registry of HA-1A (Centwdn) in septic shock. A cohort study of 600 patients. Arch. Intern. Med. (1994) 154:2484–2491.
   Google Scholar
• QUEZADO ZM, NATANSON C, ALLING DW et al: A controlled trial of HA-1A in a canine model of Gram-negative septic shock. JAMA (1993) 269:2221–2227.
   PubMedGoogle Scholar
• GREENMAN RL, SCHEIN RIVI, MARTIN MA et al: A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of Gram-negative sepsis. JAMA (1991) 266:1097–1102.
   PubMed Web of Science ®Google Scholar
• BONE RC, BALK RA, FEIN AM et al: Asecond large controlled clinical study of E5, a monoclonal antibody to endotoxin: Results of a prospective, multicenter, randomized, controlled trial. Crit. Care Med. (1995) 23:994–1006.
   PubMed Web of Science ®Google Scholar
• ANGUS DC, BIRMINGHAM MC, BALK RA et al.: E5 murine monoclonal antiendotoxin antibody in Gram-negative sepsis: A randomized controlled trial. JAMA (2000) 283: 1723-1730.
   Google Scholar
• RIETSCHEL ET, BRADE H, HOLST 0 et al: Bacterial endotoxin: Chemical constitution, biological recognition, host response, and immunological detoxification. Can: Top. Microbiol. Immunol. (1996) 216:39–81.
   Google Scholar
• WARREN HS, AMATO SF, FITTING C et al: Assessment of ability of murine and human anti-lipid A monoclonal antibodies to bind and neutralize lipopolysaccharide. Exp. Med. (1993) 177:89–97.
   PubMed Web of Science ®Google Scholar
• DI PADOVA FE, BRADE H, BARCLAY GR et al.: A broadly cross-protective monoclonal antibody binding to Escherichia coil and Salmonella lipopolysaccharides. Infect. Immun. (1993) 61:3863–3872.
   PubMed Web of Science ®Google Scholar
• BAHRAMI S, YONG-MING Y, LEICHTFRIED G, REDL H, SCHLAG G, DI PADOVA FE: Monoclonal antibody to endotoxin attenuates hemorrhage-induced lung injury and mortality in rats. Grit. Care Med. (1997) 25:1030–1036.
   PubMed Web of Science ®Google Scholar
• BAILAT S, HEUMANN D, LE ROY D et al: Similarities and disparities between core-specific and 0-side-chain-specific antilipopolysaccharide monoclonal antibodies in models of endotoxemia and bacteremia in mice. Infect. Immun. (1997) 65:811–814.
   PubMed Web of Science ®Google Scholar
• BHATTACHARJEE AK, OPAL SM, TAYLOR R et al: A noncovalent complex vaccine prepared with detoxified Escherichia J5 (Rc chemotype) lipopolysaccharide and Neisseria meningitides Group B outer membrane protein produces protective antibodies against Gram-negative bacteremia. Infect. Dis. (1996) 173:1157-63. ao.ANTAL-SZALMAS P: Evaluation of CD14 in host defense. Eur: Clin. Invest. (2000) 30:167–179.
   Google Scholar
• ••
   Google Scholar
• FREVERT CW, MATUTE-BELLO G, SKERRETT SJ et al: Effect of CD14 blockade in rabbits with Escherichia coil pneumonia and sepsis. I Immunol. (2000) 164:5439–5445.
   PubMed Web of Science ®Google Scholar
• LETURCQ DJ, MORIARTY AM, TALBOTT G et al: Antibodies against CD14 protect primates from endotoxin-induced shock. Clin. Invest. (1996) 98:1533–1538.
   Google Scholar
• SCHIMKE J, MATHISON J, MORGIEWICZ J et al: Anti-CD14 mAb treatment provides therapeutic benefit after in vivo exposure to endotoxin. Proc. Nati Acad. Sri. USA (1998) 95:13875–13880.
   PubMed Web of Science ®Google Scholar
• ARNDT P, ABRAHAM E: Immunological therapy of sepsis: Experimental therapies. Intensive Care Med. (2001) 27:S104–S115.
   PubMed Web of Science ®Google Scholar
• VERBON A, DEKKERS PE, TEN HOVE T et al: IC14, and anti-CD14 antibody, inhibits endotoxin-mediated symptoms and inflammatory responses in humans. Immunol. (2001) 165:3599–3605.
   Google Scholar
• AXTELLE T, PRIBBLE J: IC14, a CD14 specific monoclonal antibody, is a potential treatment fro patients with severe sepsis. Endotoxin Res. (2001) 7:310–314.
   PubMedGoogle Scholar
• WENNERAS C, AVE P, HUERRE M et al.: Blockade of CD14 increases Shigella-mediated invasion and tissue destruction. Immunol. (2000) 164:3214–3221.
   Web of Science ®Google Scholar
• INGALLS RR, HEINE H, LIEN E, YOSHIMURA A, GOLENBOCK D: Lipopolysaccharide recognition, CD14, and lipopolysaccharide receptors. Infect. Dis. Clin. North Am. (1999) 13:341–353.
   PubMed Web of Science ®Google Scholar
• •Good review of the innate immune response to LPS.
   Google Scholar
• LANDMANN R, ZIMMERLI W, SANSANO S et al.: Increased circulating soluble CD14 is associated with high mortality in Gram-negative septic shock.' Infect. Dis. (1995) 171:639–644.
   Google Scholar
• GRUNWALD U, KRUGER C, SCHUTT C: Endotoxin-neutralizing capacity of soluble CD14 is a highly conserved specific function. Circ. Shock (1993) 39:220–225.
   PubMedGoogle Scholar
• HAZIOT A, RONG GW, LIN X et al: Recombinant soluble CD14 prevents mortality in mice treated with endotoxin (lipopolysaccharide). Immunol. (1995) 154:6529–6532.
   Web of Science ®Google Scholar
• HAILMAN E, LICHENSTEIN HS, WURFEL MM et al: Lipopolysaccharide (LPS)-binding protein accelerates the binding of LPS to CD14. 1. Exp. Med. (1994) 179:269–277.
   Google Scholar
• LAMPING N, DETTMER R, SCHRODER NW et al: LPS-binding protein protects mice from septic shock caused by LPS or Gram-negative bacteria.' Clin. Invest. (1998) 101:2065–2071.
   Google Scholar
• GALLAY P, HEUMANN D, LE ROY D, BARRAS C, GLAUSER MP: Mode of action of antilipopolysaccharide-binding protein antibodies for prevention of endotoxemic shock in mice. Proc. Natl. Acad. Sci. USA (1994) 91:7922–7926.
   PubMed Web of Science ®Google Scholar
• LE ROU S, DI PADOVA FE, TEES R et al.: Monoclonal antibodies to murine lipopolysaccharide (LPS)-binding protein (LBP) protect mice from lethal endotoxemia by blocking either the binding of LPS to LBP or the presentation to LPS/LBP complexes to CD14. 1 Immunol. (1999) 162:7454–7460.
   Google Scholar
• GAZZANO-SANORO H, PARENT JB, GRINNA L et al.: High-affinity binding of bactericidal/permeability increasing protein and a recombinant amino-terminal fragment to the lipid A region of lipopolysaccharide. Infect. Inman. (1992) 60:4754–4761.
   PubMed Web of Science ®Google Scholar
• GIROIR BP, SCANNON PJ, LEVIN M: Bactericidal/permeability increasing protein - Lessons learned from the Phase III, randomized, clinical trial of rBPI21 for adjunctive treatment of children with severe meningococcemia. Grit. Care Med. (2001) 29:S130–S135.
   PubMed Web of Science ®Google Scholar
• ••Excellent review of the evidence for rBPI.
   Google Scholar
• BAUER RJ, WHITE ML, WEDEL N et al.: A Phase I safety and pharmacokinetics study of recombinant amino terminal fragment of bactericidal/permeability increasing protein in health male volunteers. Shock (1996) 5:91–96.
   PubMed Web of Science ®Google Scholar
• VON DER MOHLEN MA, KIMMINGS AN, WEDEL NI et al: Inhibition of endotoxin-induced cytokine release and neutrophil activation in humans by use of recombinant bactericidal/permeability increasing protein.' Infect. Dis. (1995) 172:144–151.
   Google Scholar
• DE WINTER RJ, VON DER MOHLEN MA, VAN LIESHOUT et al.: Recombinant endotoxin-binding protein (rBPI23) attenuates endotoxin-induced circulatory changes in humans. I Inflamm. (1995) 45:193–206.
   Google Scholar
• VON DER MOHLEN MA, VAN DEVENTER SJ, LEVI M et al.: Inhibition of endotoxin-induced activation of the coagulation and fibrinolytic pathways using a recombinant endotoxin binding protein (rBPI23). Blood (1995) 85:3437–3443.
   Google Scholar
• GIROIR BP, QUINT PA, BARTON P et al.: Preliminary evaluation of recombinant amino-terminal fragment of human bactericidal/permeability increasing protein in children with severe meningococcal sepsis. Lancet (1997) 350:1439–1443.
   PubMed Web of Science ®Google Scholar
• LEVIN M, QUINT PA, GOLDSTEIN B et al.: Recombinant bactericidal/ permeability increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: A randomized trial. Lancet (2000) 356:961–967.
   PubMed Web of Science ®Google Scholar
• ••Promising study of the use of rBPI inmeningococcal sepsis.
   Google Scholar
• DEMETRIADES D, SMITH JS, JACOBSON LE et al: Bactericidal/ permeability increasing protein (rBPI21) in patients with hemorrhage due to trauma: Results of a multicenter Phase II clinical trial. rBPI21 Acute Hemorrhagic Trauma Study Group. I Trauma (1999) 46:667–676.
   Google Scholar
• ABRAHAMSON SL, WU HM, WILLIAMS RE et al.: Biochemical characterization of recombinant fusions of lipopolysaccharide binding protein and bactericidal/permeability increasing protein. Implications in biological activity. I. Biol. Chem. (1997) 272:2149–2155.
   PubMed Web of Science ®Google Scholar
• YANG D, CHERTOV 0, OPPENHEIM JJ: The role of mammalian antimicrobial peptides and proteins in awakening of the innate host defenses and adaptive immunity. Cell. MM. Life ScL (2001) 58:978–989.
   PubMed Web of Science ®Google Scholar
• LARRICK JVV, HIRATA M, BALINT RF, LEE J, ZHONG J, WRIGHT SC: Human CAP18: a novel antimicrobial lipopolysaccharide-binding protein. Infect. Immun. (1995) 63:1291–1297.
   PubMed Web of Science ®Google Scholar
• KIRIKAE T, HIRATA M, YAMASU H et al.: Protective effects of human 18-kilodalton cationic antimicrobial protein (CAP18)-derived peptide against murine endotoxemia. Infect. Immun. (1998) 66:1861–1868.
   PubMed Web of Science ®Google Scholar
• WARREN HS, GLENNON ML, WAINWRIGHT N et al.: Binding and neutralization of endotoxin by Limulus antilipopolysaccharide factor. Infect. Immun. (1992) 60:2506–2513.
   PubMed Web of Science ®Google Scholar
• VANDER MEER TJ, MENCONI MJ, ZHUANG J et al.: Protective effects of a novel 32-amino acid C-terminal fragment of CAP18 in endotoxemic pigs. Surgery (1995) 117:656–662.
   PubMed Web of Science ®Google Scholar
• FLETCHER MF, KLOZEWIAK M, LOISELLE PM et al.: A peptide-IgG conjugate, CAP18106438-IgG that binds and neutralizes endotoxin and kills Gram-negative bacteria. Infect. Dis. (1997) 175:621–626.
   Google Scholar
• WATSON RW, REDMOND HP, MC CARTHY J, BOUCHIER-HAYES D: Taurolidine, an antilipopolysaccharide agent, has immunoregulatory properties that are mediated by the amino acid taurine. .1. Leukoc. Biol. (1995) 58:299–306.
   PubMed Web of Science ®Google Scholar
• BEDROSIAN I, SOFIA RD, WOLFF SM, DINARELLO CA: Taurolidine, an analogue of the amino acid taurine, suppresses interleukin 1 and tumor necrosis factor synthesis in human peripheral blood mononuclear cells. Cytokine (1991) 3:568–75.
   PubMed Web of Science ®Google Scholar
• WILLATTS SM, RADFORD S, LEITERMANN M: Effect of the antiendotoxic agent, taurolidine, in the treatment of sepsis syndrome: a placebo-controlled, double-blind trial. Crit. Care Med (1995) 23:1033–1039.
   PubMed Web of Science ®Google Scholar
• KUPPERMANN N, NELSON DS, SALADINO RA et al.: Comparison of a recombinant endotoxin-neutralizing protein with a human monoclonal antibody to endotoxin for the treatment of Escherichia colisepsis in rats.' Infect. Dis. (1994) 170:630–635.
   Google Scholar
• GARCIA C, SALADINO R, THOMPSON C et al: Effect of a recombinant endotoxin-neutralizing protein on endotoxin shock in rabbits. Crit. Care Med. (1994) 22:1211–1218.
   PubMed Web of Science ®Google Scholar
• NELSON D, KUPPERMANN N, FLEISHER GR et al.: Recombinant endotoxin neutralizing protein improves survival from Escherichia colisepsis in rats. Crit. Care Med. (1995) 23:92–98.
   PubMed Web of Science ®Google Scholar
• SALADINO RA, STACK AM, THOMPSON C et al: High-dose recombinant endotoxin neutralizing protein improves survival in rabbits with Escherichia colisepsis. Crit. Care Med. (1996) 24:1203–1207.
   PubMed Web of Science ®Google Scholar
• WEINER DL, KUPPERMANN N, SALADINO RA et al.: Comparison of early and late treatment with a recombinant endotoxin neutralizing protein in a rat model of Escherichia colisepsis. Grit. Care Med. (1996) 24:1514–1517.
   PubMed Web of Science ®Google Scholar
• STACK AM, SALADINO RA, SIBER GR et al.: A comparison of bactericidal/ permeability increasing protein variant versus recombinant endotoxin neutralizing protein for the treatment of Escherichia coil sepsis in rats. Grit. Care Med. (1997) 26:101–105.
   Google Scholar
• ALPERT G, BALDWIN G, THOMPSON C et al.: Limulus antilipopolysaccharide factor protects rabbits from meningococcal endotoxin shock. Infect. Dis. (1992) 165:494–500.
   Google Scholar
• ROTH RI, SU S, CHILD AH, WAINWRIGHT NR, LEVIN J: Limulus antilipopolysaccharide factor prevent mortality late in the course of endotoxemia. Infect. Dis. (1998) 177:388–394.
   Google Scholar
• DANNER RL, JOINER KA, RUBIN M et al.: Purification, toxicity, and antiendotoxin activity of polymyxin B nonapeptide. Antimicrob. Agents Chemother. (1989) 33:1428–1434.
   PubMed Web of Science ®Google Scholar
• MAYUMI T, TAKEZAWA J, TAKAHASHI H et al.: Low-dose intramuscular polymyxin B improves survival of septic rats. Shock (1999) 11:82–86.
   PubMed Web of Science ®Google Scholar
• ENDO S, INADA K, INOUE Y et al: Treatment of endotoxemia with low-dose intramuscular injections or oral administration of polymyxin B. Clin. Ther. (1992) 14:64–67.
   PubMed Web of Science ®Google Scholar
• GIACOMETTI A, CIRIONI 0, GHISELLI R et al.: Therapeutic efficacy of intraperitoneal polymyxin B and polymyxin-like peptides alone or combined with levofloxicin in rat models of septic shock. Antimicrob. Chemother. (2002) 49:193–196.
   Google Scholar
• GHISELLI R, GIACOMETTI A, CIRIONI 0 et al: Therapeutic efficacy of the polymyxin-like peptide ranalexin in an experimental model of endotoxemia. Surg. Res. (2001) 100:183–188.
   PubMed Web of Science ®Google Scholar
• BUCKLIN SE, LAKE P, LOGDBERG L, MORRISON DC: Therapeutic efficacy of a polymyxin B-dextran 70 conjugate in experimental model of endotoxemia. Antimicrob. Agents Chemother. (1995) 39:1462–1466.
   PubMed Web of Science ®Google Scholar
• DOIG GS, MARTIN CM, SIBBALD WJ: Polymyxin-dextran antiendotoxin pretreatment in an ovine model of normotensive sepsis. Crit. Care Med. (1997) 25:1956–1961.
   PubMed Web of Science ®Google Scholar
• DRABICK JJ, BHATTACHARJEE AK, HOOVER DL et al.: Covalent polymyxin B conjugate with human immunoglobulin G as an antiendotoxin reagent. Antimicrob. Agents Chemother. (1998) 42:583–588.
   PubMed Web of Science ®Google Scholar
• READ TE, HARRIS HW, GRUNFELD C et al.: Chylomicrons enhance endotoxin excretion in bile. Infect. Immun. (1993) 61:3496–3502.
   PubMed Web of Science ®Google Scholar
• EMANCIPATOR K, CSAKO G, ELIN RJ: In vitro inactivation of bacterial endotoxin by human lipoproteins and apolipoproteins. Infect. Immun. (1992) 60:596–601.
   PubMed Web of Science ®Google Scholar
• WURFEL MM, KUNITAKE ST, LICHENSTEIN H, KANE JP, WRIGHT SD: Lipopolysaccharide (LPS)-binding protein is carried on lipoproteins and acts as a cofactor in the neutralization of LPS. Exp. Med. (1994) 180:1025–1035.
   PubMed Web of Science ®Google Scholar
• WURFEL MM, HAILMAN E, WRIGHT SD: Soluble CD14 acts as a shuttle in the neutralization of lipopolysaccharide (LPS) by LPS-binding protein and reconstituted high density lipoprotein. j Exp. Med. (1995) 181:1743–1754.
   PubMed Web of Science ®Google Scholar
• GOLDFARB RD, PARKER TS, LEVINE DM et al.: Protein free phospholipid emulsion treatment improved cardiopulmonary function and survival in porcine sepsis. Am. J Physic]. (2002): (In press).
   Google Scholar
• FLEGEL WA, BAUMSTARK MW, WEINSTOCK C, BERG A, NORTHOFF: Prevention of endotoxin-induced monokine release by human low- and high-density lipoproteins and by lipoprotein A-1. Infect. Inman. (1993) 61:5140–5146.
   PubMed Web of Science ®Google Scholar
• CUE JI, DIPIRO JT, BRUNNER LJ et al.: Reconstituted high-density lipoprotein inhibits physiologic and tumor necrosis factor alpha responses to lipopolysaccharide in rabbits. Arch. Surg. (1994) 129:193–197.
   PubMed Web of Science ®Google Scholar
• PARKER TS, LEVINE DM, CHANG JC, LAXER J, COFFIN CC, RUBIN AL: Reconstituted high-density lipoprotein neutralizes Gram-negative bacterial lipopolysaccharides in human whole blood. Infect. Immun. (1995) 63:253–258.
   PubMed Web of Science ®Google Scholar
• GORDON BR, PARKER TS, LEVINE DM et al: Relationship of hypolipidemia to cytokine concentrations and outcomes in critically ill surgical patients. Crit. Care Med. (2001) 29:1563–1568.
   PubMed Web of Science ®Google Scholar
• GORDON BR, PARKER TS, LEVINE DM et al.: Low lipid concentrations in critical illness: implications for preventing and treating endotoxemia. Crit. Care Med. (1996) 24:584–589.
   PubMedGoogle Scholar
• FEINGOLD KR, FUNK JL, MOSER AH, SHIGENAGAJK, RAPP JH, GRUNFELD C: Role for circulating lipoproteins in protection from endotoxin toxicity. Infect. Litman. (1995) 63:2041–2046.
   PubMed Web of Science ®Google Scholar
• READ TE, GRUNFLED C, KUMWENDA Z et al.: Triglyceride rich lipoproteins improve survival when given after endotoxin in rats. Surgery (1995) 117:62–67.
   PubMed Web of Science ®Google Scholar
• LEVINE DM, PARKER TS, DONNELLY TM, WALSH A, RUBIN AL: In vivo protection against endotoxin by plasma high density lipoprotein. Proc. Nati Acad. Sci. USA (1993) 90:12040–12044.
   PubMed Web of Science ®Google Scholar
• READ TE, GRUNFELD C, KUMWENDA ZL et al.: Triglyceride-rich lipoproteins prevent septic death in rats." Exp. Med. (1995) 182:267–272.
   Google Scholar
• HUBSCH AP, CASAS AT, DORAN JE: Protective effects of reconstituted high-density lipoprotein in rabbit Gram-negative bacteremia models. I Lab. Clin. Med. (1995) 126:548–558.
   PubMedGoogle Scholar
• CASAS AT, HUBSCH AP, DORAN JE: Effects of reconstituted high-density lipoprotein in persistent Gram-negative bacteremia. Am. Surg. (1996) 62:350–355.
   PubMed Web of Science ®Google Scholar
• VAN DER POLL T, BRAXTON CC, COYLE SM et al.: Effect of hypertriglyceridemia on endotoxin responsiveness in humans. Infect. Immun. (1995) 63:3396–3400.
   Google Scholar
• HARRIS HW, JOHNSON JA, WIGMORE SJ: Endogenous lipoproteins impact the response to endotoxin in humans. Crit. Care Med. (2002) 30:23–31.
   PubMed Web of Science ®Google Scholar
• PAJKRT D, DORAN JE, KOSTER F et al: Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia. Exp. Med. (1996) 184:1601–1608.
   PubMed Web of Science ®Google Scholar
• PAJKRT D, LERCH PG, VAN DER POLL T et al.: Differential effects of reconstituted high-density lipoprotein on coagulation, fibrinolysis and platelet activation during human endotoxemia. Thromb. Haemost. (1997) 77:303–307.
   Google Scholar
• QUEZADO ZM, NATANSON C, BANKS SM et al.: Therapeutic trial of reconstituted human high-density lipoprotein in a canine model of Gram-negative septic shock. Pharmacol. Exp. Ther. (1995) 272:604–611.
   PubMed Web of Science ®Google Scholar
• GOLENBOCK DT, LEGGETT JE, RASMUSSEN P et al.: Lipid X protects mice against fatal Escherichia cot/infection. Infect. Immun. (1988) 56:779–784.
   PubMed Web of Science ®Google Scholar
• GOLENBOCK DT, WILL JA, RAETZ CR et al.: Lipid X ameliorates pulmonary hypertension and protects sheep from death due to endotoxin. Infect. Litman. (1987) 55:2471–2476.
   PubMed Web of Science ®Google Scholar
• DANNER RL, EICHACKER PQ, DOERFLER ME et al.: Therapeutic trial of lipid X in a canine model of septic shock." Infect. Dis. (1993) 167:378–384.
   Google Scholar
• SATO K, Y00 YC, FUKUSHIMA A et al.: A novel synthetic lipid A analogue with low endotoxicity, DT-5461, prevents lethal endotoxemia. Infect. Immun. (1995) 63:2859–2866.
   Google Scholar
• AIDA Y, KUSUMOTO K, NAKATOMI K, TAKADA H, PABST MJ, MAEDA K: An analogue of lipid A and LPS from Rhodobacter sphaeroides inhibits neutrophil responses to LPS by blocking receptor recognition of LPS and by depleting LPS-binding protein in plasma.' Leukoc. Biol. (1995) 58:675–682.
   PubMed Web of Science ®Google Scholar
• GOLENBOCK DT, HAMPTON RY, QURESHI N, TAKAYAMA K, RAETZ CH: Lipid A-like molecules that antagonize the effects of endotwdns on human monocytes.J. Biol. Chem. (1991) 266:19490–19498.
   PubMed Web of Science ®Google Scholar
• CHRIST WJ, ASANO 0, ROBIDOUX AL et al.: E5531, a pure endotoxin antagonist of high potency. Science (1995) 268:80–83.
   Google Scholar
• BUNNELL E, LYNN M, HABET K et al.: A lipid A analog, E5531, blocks the endotoxin response in human volunteers with experimental endotoxemia. Crit. Care Med. (2000) 28:2713–2720.
   PubMed Web of Science ®Google Scholar
• YANG H, DAUN JM, ROSE JR, CHRIST WJ, GUSOVSKY F, CHOW JC: Examination of chlorpromazine and other amphipathic drugs on the activity of lipopolysaccharide antagonists, E5564 and E5531.j Endotoxin. Res. (2000) 6:447–452.
   PubMedGoogle Scholar
• WEST MA, HEAGY W: Endotwdn tolerance: A review. Grit. Care Med. (2002) 30:S64–S73.
   Google Scholar
• CARPATI CM, ASTIZ ME, RACKOW EC, KIM JW, KIM YB, WEIL MH: Monophosphoryl lipid A attenuates the effects of endotoxic shock in pigs." Lab. Clin. Med. (1992) 119:346–353.
   PubMed Web of Science ®Google Scholar
• ASTIZ ME, SAHA DC, CARPATI CM, RACKOW EC: Induction of endotoxin tolerance with monophosphoryl lipid A in peritonitis: importance of localized therapy. Lab. Clin. Med. (1994) 123:89–93.
   PubMedGoogle Scholar
• ASTIZ ME, GALERA A, SAHA SC, CARPATI CM, RACKOW EC: Monophosphoryl lipid A protects against Gram-positive sepsis and tumor necrosis factor. Shock (1994) 2:271–274.
   PubMed Web of Science ®Google Scholar
• CARPATI CM, ASTIZ ME, SAHA DC, RACKOW EC: Diphosphoryl lipid A from Rhodopseudomonas sphaeroides induces tolerance to endotoxic shock in the rat. Grit. Care Med. (1993) 21:753–758.
   PubMed Web of Science ®Google Scholar
• ASTIZ ME, RACKOW EC, STILL JG et al.: Pretreatment of normal humans with Monophosphoryl lipid A induces tolerance to endotoxin: A prospective, double-blind, randomized, controlled trial. Crit. Care Med. (1995) 23:9–17.
   PubMed Web of Science ®Google Scholar
• HANASAWA K, TANI T, KODAMA: New approach to endotoxic and septic shock by means of polymyxin B immobilized fiber. Surg. Cynecol. Obstet. (1989) 168:323–331.
   PubMedGoogle Scholar
• JABER BL, BARRETT IW, CENDOROGLO NETO M, SUNDARAM S, KING AJ, PEREIRA BJ: Endotwdn removal by polymyxin-B immobilized polystyrene-derivative fibers during in vitro hemoperfusion of 10% human plasma. ASAIDI. (1998) 44:54–61.
   PubMed Web of Science ®Google Scholar
• CHEADLE WG, HANASAWA K, GALLINARO RN, NIMMANWUDIPONG T, KODAMA M, POLK HC: Endotwdn filtration and immune stimulation improve survival from Gram-negative sepsis. Surgery (1991) 110:785–792.
   PubMed Web of Science ®Google Scholar
• HANASAWA K, AOKI H, YOSHIOKA T, MATSUDA K, TANI T, KODAMA M: Novel mechanical assistance in the treatment of endotoxic and septicemic shock. ASAIO Trans. (1989) 35:341–343.
   PubMedGoogle Scholar
• SATO T, ORLOWSKI JP, ZBOROWSKI M: Experimental study of extracorporeal perfusion for septic shock. ASAIDI. (1993) 39:M790–M793.
   PubMedGoogle Scholar
• AOKI H, KODAMA M, TANI T, HANSAWA K: Treatment of sepsis by extracorporeal elimination of endotoxin using polymyxin B-immobilized fiber. Am. Surg. (1994) 167:412–417.
   Google Scholar
• TANI T, HANASAWA K, ENDO Y et al.: Therapeutic apheresis for septic patients with organ dysfunction: Hemoperfusion using a polymyxin B immobilized column. Artif Organs (1998) 22:1038–1044.
   PubMed Web of Science ®Google Scholar
• DE VRIESE AS, COLARDYN FA, PHILIPPE JJ, VANHOLDER RC, DE SUTTER JH, LAMEIRE NH: Cytokine removal during continuous hemofiltration in septic patients. Am. Soc. Nephrol. (1999) 10:846–853.
   PubMed Web of Science ®Google Scholar
• JOHN S, GRIESBACH D, BAUMGARTEL M, WEIHPRECHT H, SCHMIEDER RE, GEIGER H: Effects of continuous haemofiltration versus intermittent haemodialysis on systemic haemodynamics and splanchnic regional perfusion in septic shock patients: a prospective, randomized clinical trial. Nephrol. Dial. Transplant. (2001) 16:320–327.
   PubMed Web of Science ®Google Scholar
• COLE L, BELLOMO R, HART G et al: A Phase II randomized, controlled trial of continuous hemofiltration in sepsis. Grit. Care Med. (2002) 30:100–106.
   PubMed Web of Science ®Google Scholar
• VAN DEUREN M, SANTMAN FW, VAN DALEN R, SAUERWEIN RW, SPAN LF, VAN DER MEER JW: Plasma and whole blood exchange in meningococcal sepsis. Clin. Infect. Dis. (1992) 15:424–430.
   PubMed Web of Science ®Google Scholar
• GARDLUND B, SJOLIN J, NILSSON A et al.: Plasmapheresis in the treatment of primary septic shock in humans. Scand. .1. Infect. Dis. (1993) 25:757–761.
   Google Scholar
• NATANSON C, HOFFMAN WD, KOEV LA et al: Plasma exchange does not improve survival in canine model of human septic shock. Transfusion (1993) 33:243–248.
   PubMed Web of Science ®Google Scholar
• REEVES JH, BUTT WW, SHANN F et al.: Continuous plasmafiltration in sepsis syndrome. Crit. Care Med. (1999) 27:2069–2104.
   PubMedGoogle Scholar
• NOVOGRODSKY A, VANICHKIN A, PATYA M, GAZIT A, OSHEROV N, LEVITZKI A: Prevention of lipopolysaccharide-induced lethal toxicity by tyrosine kinase inhibitors. Science (1994) 264:1319–1322.
   PubMed Web of Science ®Google Scholar
• OGURA S, UMEGAKI 0, GENOVESE F et al.: Protective effect of tyrophostin AG 556 on shock induced by endotoxin or Gram-positive bacteria. Shock (1999) 12:105–110.
   Google Scholar
• VANICHKIN A, PATYA M, GAZIT A, LEVITZKI A, NOVOGRODSKY A: Late administration of lipophilic tyrosine kinase inhibitor prevents lipopolysaccharide and Escherichia collinduced lethal toxicity. J. Infect. Dis. (1996) 173:927–933.
   PubMed Web of Science ®Google Scholar
• SEVRANSKY JE, SHAKED G, NOVOGRODSKY A et al.: Tyrphostin AG 556 improves survival and reduces multiple organ failure in canine Escherichia coil peritonitis. .1. Clin. Invest. (1997) 99:1966–1973.
   Google Scholar
• DANNER RL, ELIN RJ, HOSSEINI JM, WESLEY RA, REILLY JM, PARRILLO JE: Endotoxemia in human septic shock. Chest (1991) 99:169–175.
   PubMed Web of Science ®Google Scholar
• MUNFORD RS, HALL CL: Detoxification of bacterial lipopolysaccharides (endotwdns) by a human neutrophil enzyme. Science (1986) 234:203–205.
   PubMed Web of Science ®Google Scholar
• PANACEK EA, MACARTHUR RD, JOHNSON SB: Results of a Phase III clinical trial of the human monoclonal antibody Mab-T88 versus placebo in Gram-negative sepsis. Society of Critical Care Medicine, San Francisco, USA (1995):A293.
   Google Scholar
• CIRIONI 0, GIACOMETTI A, GHISELLI R et al.: Single-dose intraperitoneal magainins improve survival in a Gram-negative pathogen septic shock rat model. Antimicrob. Agents Chemother: (2002) 46:101–104.
   Google Scholar
• GIACOMETTI A, CIRIONI 0, GHISELLI R et al.: Potential therapeutic role of cationic peptides in three experimental models of septic shock. Antimicrob. Agents Chemother. (2002) 46:2132–2136.
   Google Scholar
• SCOTT MG, VREUGDENHIL AC, BUURMAN WA, HANCOCK RE, GOLD MR: Cutting edge: Cationic antimicrobial peptides block the binding of lipopolysaccharide (LPS) to LPS binding protein. J. Immunol. (2000) 164:549–553.
   PubMed Web of Science ®Google Scholar
• GOUGH M, HANCOCK RE, KELLY NM: Antiendotoxin activity of cationic peptide antimicrobial agents. Infect. Immun. (1996) 64:4922–4927.
   PubMed Web of Science ®Google Scholar
• YOUNG LS, MARTIN WJ, MEYER RD, WEINSTEIN RJ, ANDERSON ET: Gram-negative rod bacteremia: microbiologic, immunologic, and therapeutic considerations. Ann. Intern. Med. (1977) 86:456-471. Affiliation
   Google Scholar